EUCTR2009-013762-63-IT进行中（未招募）不适用
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophy - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Age at least 5 and not older than 16 years on the day of first drug administration 2. Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO044 3. Life expectancy at least 6 months after inclusion in the trial
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Ventilator dependency 2. Previous treatment with investigational medicinal treatment within 6 months prior to the start of the pre-screening of the study 3. Previous treatment with idebenone within 6 months prior to the start of the pre-screening for the study
研究者
相似试验
进行中（未招募）
不适用
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2009-013762-63-NLProsensa Therapeutics B.V18
进行中（未招募）
1 期
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2009-013762-63-BEProsensa Therapeutics B.V24
进行中（未招募）
不适用
A study to assess the effect and safety of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchenne DiseaseMedDRA version: 14.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2009-013762-63-SEProsensa Therapeutics B.V24
进行中（未招募）
不适用
A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystrophyMedDRA version: 9.1Level: LLTClassification code 10013801Term: Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2007-004819-54-NLProsensa Holding B.V.18
进行中（未招募）
1 期
A study to assess the effect and safety of multiple subcutaneous doses of drisapersen in patients with Duchenne DiseaseDuchenne Muscular DystrophyMedDRA version: 17.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-004819-54-BEProsensa Therapeutics BV12